Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab

Cancer Research

Volumn 63, Issue 1, 2003, Pages 36-38

  Byrd, John C ^a   Smith, Lisa ^a   Hackbarth, Marcy L ^b   Flinn, Ian W ^c   Young, Donn ^a   Proffitt, John H ^b   Heerema, Nyla A ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 11; CHROMOSOME 13; CHROMOSOME 17; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; INTERPHASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037228952     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jarosova, M., Jedlickova, K., Holzerova, M., Urbanova, R., Papajik, T., Raida, L., Pikalova, Z., Lakoma, I., Prekopova, I., Kropackova, J., and Indrak, K. Contribution of comparative genomic hybridization and fluorescence in situ hybridization to the detection of chromosomal abnormalities in B-cell chronic lymphocytic leukemia. Onkologie, 24: 60-65, 2001.
2. Callet-Bauchu, E., Salles, G., Gazzo, S., Poncet, C., Morel, D., Pages, J., Coiffier, B., Coeur, P., and Felman, P. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome. Leukemia (Baltimore), 13: 460-468, 1999.
3. Cano, I., Martinez, J., Quevedo, E., Pinilla, J., Martin-Recio, A., Rodriguez, A., Castaneda, A., Lopez, R., Perez-Pino, T. and Hernandez-Navarro, F. Trisomy 12 and p53 deletion in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: association with morphology and resistance to conventional chemotherapy. Cancer Genet. Cytogenet., 90: 118-124, 1996.
4. Dohner, H., Stilgenbauer, S., James, M. R., Benner, A., Weilguni, T., Bentz, M., Fischer, K., Hunstein, W., and Lichter, P. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood, 89: 2516-2522, 1997.
5. Chevallier, P., Penther, D., Avet-Loiseau, H., Robillard, N., Ifrah, N., Mahe, B., Hamidou, M., Maisonneuve, H., Moreau, P., Jardel, H., Harousseau, J. L., Bataille, R., and Garand, R. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br. J. Haematol., 116: 142-145, 2002.
6. Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., and Lichter, P. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85: 1580-1589, 1995.
7. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M., and Lichter, P. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med., 343: 1910-1916, 2000.
8. Cheson, B. D., Bennett, J. M., Grever, M., Kay, N., Keating, M. J., O'Brien, S., and Rai, K. R. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87: 4990-4997, 1996.
9. Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., Pearson, M., Waselenko, J. K., Ling, G., Grever, M. R., Grillo-Lopez, A. J., Rosenberg, J., Kunkel, L., and Flinn, I. W. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol., 19: 2153-2164, 2001.
10. M. S. Watson (Ed.) American College of Medical Genetics, Standards and Guidelines for Clinical Genetics Laboratories, Ed. 2, pp. 23-36. Bethesda, MD: American College of Medical Genetics, 1999.
11. Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H., and Jurlander, J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood, 99: 1314-1319, 2002.
12. Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., and Reed, J. C. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 99: 1038-1043, 2002.
13. Stilgenbauer, S., Scherer, K., Krober, A., Bullinger, L., Hochsmann, B., Mayer-Steinacker, R., Bunjes, D., and Dohner, H. Campath-1H in refractory B-CLL-Complete Remission Despite p53 gene mutation. Blood, 98: 771, 2001.
14. Byrd, J. C., Peterson, B. L., Morrison, B. L., Park, K., Jacobson, R., Hoke, E., Rai, K., Schiffer, C. A., and Larson, R. A. Randomized phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from CALGB 9712. Blood, in press, 2002.
15. Wierda, W., O'Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Fader, S., Thomas, D., Koller, C., Kantarjian, H., and Keating, M. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment of chronic lymphocytic leukemia. Blood, 98: 721, 2001.